Tag: non-small cell lung cancer (NSCLC)

1. Concomitant pembrolizumab plus chemoradiation therapy was associated with improved antitumor activity and safety profile in patients with previously untreated, locally advanced, stage III non-small cell lung cancer. 2. This treatment regimen represents a promising therapy in patients with previously untreated, locally advanced, stage III non-small cell lung cancer, regardless...
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.  Evidence Rating Level: 1 (Excellent) Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death ligand 1 (PD-L1)...
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.  Evidence Rating Level: 1 (Excellent) Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death...
1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib. 2. Lorlatinib treated patients had improved overall cancer response including greater intracranial response. Evidence Rating Level: 1 (Excellent) Study Rundown: Anaplastic lymphoma kinase (ALK) chromosome rearrangement is a target for anti-cancer treatment...
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) and high programmed death 1 ligand (PD-L1) expression. 2. Atezolizumab was associated with longer progression-free survival compared to platinum-based combination chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: The first line-treatment for...
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) and high programmed death 1 ligand (PD-L1) expression. 2. Atezolizumab was associated with longer progression-free survival compared to platinum-based combination chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: The first line-treatment for...
1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded with the approval of targeted therapies 2. The improved mortality of small cell lung cancer was not driven by treatment advancement but rather a decrease in the incidence Evidence Rating Level:...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles. 2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
1. After a 3-year follow-up to a phase 3 trial, the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib resulted in a longer median overall survival versus comparator EGFR-TKIs with similar safety profiles. 2. Benefits appeared to extend across most predefined subgroups including sex, age, and smoking history, although there was...
Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective in prolonging survival in advanced non-small-cell lung cancer (NSCLC) with a PD1-ligand (PD-L1) tumor proportion score (TPS) of 50% or greater. In this randomized, open-label, phase 3 study, pembrolizumab...